Rankings / Cognitive — Nootropics
NSI-189
Cognitive · Hippocampal neurogenesis
Tier C
What this is
Ph2 MDD trial (Fava 2016) missed primary endpoint despite promising Ph1b. Neuralstem (now Palisade Bio) largely discontinued development. Sold as research chemical. Claims of hippocampal volume restoration in depression preclinical models.
Mechanism
Benzylpiperazine-aminopyridine; proposed to stimulate hippocampal neurogenesis; mechanism incompletely understood; developed by Neuralstem
Dose & route
40-80 mg/day PO in trials
Citations
- https://pubmed.ncbi.nlm.nih.gov/26620678/
- https://pubmed.ncbi.nlm.nih.gov/31129114/
- https://pubmed.ncbi.nlm.nih.gov/28457595/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.